HC Wainwright Forecasts Stronger Earnings for Urogen Pharma

Urogen Pharma (NASDAQ:URGN) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of Urogen Pharma in a note issued to investors on Thursday, August 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.07) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.17 EPS and FY2027 earnings at $1.05 EPS.

A number of other analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. TD Cowen increased their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Oppenheimer increased their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.78.

Urogen Pharma Trading Down 1.4%

Urogen Pharma stock opened at $46.31 on Monday. The stock has a fifty day moving average price of $36.83 and a 200 day moving average price of $27.37. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $48.19. The firm has a market capitalization of $2.26 billion, a P/E ratio of -23.39 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank acquired a new position in shares of Urogen Pharma during the first quarter worth $1,399,000. SG Americas Securities LLC boosted its stake in shares of Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after purchasing an additional 280,199 shares during the period. ADAR1 Capital Management LLC grew its holdings in Urogen Pharma by 139.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 395,459 shares of the company’s stock valued at $7,110,000 after purchasing an additional 230,084 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in Urogen Pharma by 8.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock valued at $6,602,000 after purchasing an additional 22,733 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in Urogen Pharma during the 4th quarter valued at $2,342,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares in the company, valued at approximately $4,790,520. The trade was a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 25,222 shares of company stock valued at $892,661. Insiders own 4.80% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.